Adriane M Zernhelt

Statistics

Publications

Citations

1.8K

H-Index

Active since

2014

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Adriane M Zernhelt is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in chemotherapy, cancer pharmacology, and oncology.

Publications per year

2014–2015

Publications

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Antoni Ribas, Igor Puzanov, Reinhard Dummer et al. · The Lancet Oncology · 2015 · 1.6K citations · Full text

Medicine, Clinical Sciences, Oncology +15

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors

L. Rhoda Molife, Yan Li, Joanna Vitfell-Rasmussen et al. · Journal of Hematology & Oncology · 2014 · 190 citations · Full text

Medicine, Oncology, Pharmacology +17

1–2 of 2